Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases of $10.14 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases · last filed 2017-11-09
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-06-30 was $0.00.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-03-31 was $0.00.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2014-12-31 was $3.17M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2014 was $3.22M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 0 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | $10.14M 10-Q · filed 2017-11-09 | ||||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $3.17M derived: sum of 3 quarters · filed 2016-03-15 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | $3.17M derived: sum of 2 quarters · filed 2016-03-15 | |||
| 2014-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $3.22M 10-K · filed 2016-03-15 | |||
| 2014-09-30 | $50.00K 10-Q · filed 2014-11-06 | ||||
| 2014-08-12 | $50.00K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |